focus -WSS

focus

author：hotspot 2025-09-30 01:53:53 - browse：828

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： STAT Wunderkinds: Ruey Hu's digital tools for parsing research

hotspot

WSS

UnitedHealth’s Optum accused of antitrust violations in California

With clinical trial data readouts, here's how to spot spin

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Traditional Chinese medicine benefits explored in new JAMA study

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Will the market for weight loss drugs really reach $100 billion?

hotspot

focus

knowledge

Jerome Adams on the need for new antivirals for Covid

Takeda, Janssen join wearable maker to measure scratching

Tori Bowie and the unacceptable rates of Black maternal death

ReNAgade cuts staff seven months after raising $300 million

Sports medicine is finally prioritizing gender equality

Mayo Clinic plans $5B tech

Drug repurposing or repositioning? The language matters

Physician subsidies by hospitals soar in wake of No Surprises Act

Anesthesiologist group: stop taking Ozempic before surgery

BIO selects John Crowley as new CEO

leisure time

With clinical trial data readouts, here's how to spot spin

Pediatric cancer treatments threatened by a new FDA policy

Fetal surgery at risk from Dobbs and new abortion restrictions

Biden's order seeks to regulate AI risk without stifling innovation

What to do when lifesaving products contribute to climate change

Meta's Zuckerberg and Chan on track to put $50 billion into science

hotspot

Wikipedia

hotspot

Wikipedia